Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.60 -0.11 (-0.43%)
Official Closing Price Updated: 4:10 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36,674,158
Open 25.76
Bid (Size) 25.62 (10)
Ask (Size) 25.66 (4)
Prev. Close 25.71
Today's Range 25.53 - 26.07
52wk Range 24.48 - 31.54
Shares Outstanding 5,606,688,356
Dividend Yield 6.56%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators (UPDATED)
Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased costs in federal health programs. 
Via Benzinga
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
Via The Motley Fool

Performance

YTD
-3.80%
-3.80%
1 Month
-1.04%
-1.04%
3 Month
+1.47%
+1.47%
6 Month
-13.69%
-13.69%
1 Year
-8.60%
-8.60%

More News

Read More
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study
Via Benzinga
10 Highest Yielding Blue Chip Stocks Now
Via Talk Markets
Topics Stocks / Equities
Looking At Pfizer's Recent Unusual Options Activity
Via Benzinga
3 Top Dividend Stocks to Buy in March
Via The Motley Fool
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
1 Stock Down 43% That Looks Too Cheap to Ignore
Via The Motley Fool
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Via Benzinga
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
Via Investor's Business Daily
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
From Arvinas Inc.
Via GlobeNewswire
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic
Via Stocktwits
Elizabeth Warren Raises Questions On Robert F Kennedy's Mar-A-Lago Dinners With Big Pharma: American People Deserve To Know About The Deals Made
Via Benzinga
Milestone Merger Payment with Predictive Oncology to Advance AI-Driven Biomarker Discovery & Precision Medicine in Cancer & Beyond: Stock Symbol: RENB
Via PRLog
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
The State of Weight Loss Drugs
Via The Motley Fool
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
Via Benzinga
Exposures COVID-19
BioNTech Surpasses Q4 Revenue Estimates
Via The Motley Fool
3 Reasons PFE is Risky and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
Exposures US Equities
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
The Nasdaq Is Falling: 4 of the Safest Stocks to Buy Right Now
Via The Motley Fool
The Smartest Dividend Stocks to Buy With $2,000 Right Now
Via The Motley Fool
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
3 Ultra-Cheap Dividend Stocks to Buy Right Now
Via The Motley Fool
Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats: 'Will The Trump Administration Co-Invest', Asks Analyst
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Most active S&P500 stocks in Monday's session
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.